|
AAML1031
|
-
|
A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD--Closed(8/16/2017)
|
|
ACNS0331
|
-
|
Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial --Closed(7/8/2015)
|
|
| |
|
AEWS1031
|
-
|
A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma--Closed(7/21/2017)
|
| |
|
ANBL09P1
|
-
|
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma --Closed(1/6/2016)
|
| |
|
ANBL12P1
|
-
|
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma --Closed(4/10/2015)
|
| |
|
AREN0534
|
-
|
Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor --Closed(6/2/2015)
|
| |
|
ARET0321
|
-
|
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma --Closed(5/5/2017)
|
| |
|
ARST-1321
|
-
|
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)--Closed(01/22/2019)
|
| |
|
AEWS1221
|
-
|
Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma--Closed
|
|
AALL1331
|
-
|
Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL).--Closed
|
|
ACNS0831
|
-
|
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years--Closed
|
|
ACNS0332
|
-
|
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients --Closed
- Temporarily closed (effective 04/16/2018)
|
|
ACNS1123
|
-
|
Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) ---Closed
|
|
ADVL1217
|
-
|
A PHASE 1 STUDY OF MK-1775 (IND# 116495) CONCURRENT WITH LOCAL RADIATION THERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMAS--Closed
|
|
AHOD1331
|
-
|
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents--Closed
|
|
ABNL17P1
|
---
|
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, dinutuximab) (NSC# 764038, IND# 4308) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma--Closed(09/2020)
|
|
ACNS1721
|
---
|
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
|